Exxon Mobil Corp
Change company Symbol lookup
Select an option...
XOM Exxon Mobil Corp
EPD Enterprise Products Partners LP
STLB Sterling Business Solutions Inc
CITY Avalon Correctional Services Inc
TEVJF Teva Pharmaceutical Industries Ltd
UMBF UMB Financial Corp
OXM Oxford Industries Inc
ICON Iconix Brand Group Inc
BAC Bank of America Corp
ON ON Semiconductor Corp
Go

Energy : Oil, Gas & Consumable Fuels | Large Cap Value
Company profile

Exxon Mobil Corporation is engaged in energy business. The Company is engaged in the exploration, production, transportation and sale of crude oil and natural gas, and the manufacture, transportation and sale of petroleum products. The Company also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and a range of specialty products. The Company's segments include Upstream, Downstream, Chemical, and Corporate and Financing. The Upstream segment operates to explore for and produce crude oil and natural gas. The Downstream operates to manufacture and sell petroleum products. The Chemical segment operates to manufacture and sell petrochemicals. The Company has exploration and development activities in projects located in the United States, Canada/South America, Europe, Africa, Asia and Australia/Oceania.

Price
Delayed
$45.81
Day's Change
1.21 (2.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
45.85
Day's Low
45.47
Volume
(Heavy Day)

Today's volume of 2,162,915 shares is on pace to be much greater than XOM's 10-day average volume of 23,353,446 shares.

2,162,915

Minerva Surgical(R) Announces Acquisition Closing of Boston Scientific Intrauterine Health Products

10:11 am ET May 12, 2020 (PR Newswire) Print

Minerva Surgical announced today, the closing of the acquisition of Boston Scientific's Intrauterine Health franchise. Minerva's combined product line will provide healthcare practitioners with the most complete and trusted product portfolio for treating Abnormal Uterine Bleeding (AUB). According to the American College of Obstetricians and Gynecologists, about one third of women seek treatment for heavy menstrual bleeding.1

https://mma.prnewswire.com/media/683278/Minerva_Surgical___Logo.jpg

The newly minted suite of minimally invasive tools combines the Minerva Endometrial Ablation System, the fastest growing endometrial ablation product, with the Genesys HTA(TM) Endometrial Ablation System, trusted for decades by physicians desiring visualization within the uterine cavity during treatment. Also included is Symphion(TM), the all-in-one tissue removal system that transforms the way physicians remove uterine fibroids, and the Resectr(TM) device for the removal of endometrial polyps.

"We are proud to have a complete product line to meet the needs of patients, whether treated in the physician's office, ambulatory surgery center, or hospital setting," said Eugene Skalnyi, M.D., Chief Medical Officer, Minerva Surgical. "The more effectively we treat the conditions that cause AUB, the more likely we are to achieve the objective of lowering the rate of hysterectomies for benign conditions, preserving the patient's uterus, and positively impacting the patient's quality of life and cost of care."

Each year in the United States, more than 400,000 women undergo the surgical removal of their uterus. A study published in the American Journal of Obstetrics and Gynecology suggests that at least 80,000 of those hysterectomies may be unnecessary and/or could be avoided.2 Some physicians still choose to perform hysterectomies instead of safe and effective minimally invasive, organ-sparing options for the treatment of benign uterine conditions, such as fibroids and endometrial polyps.

"Minerva is now AUB's worst nightmare," said Dave Clapper, President & CEO, Minerva Surgical. "We are excited to do our part to eliminate this horrible condition that too often results in unnecessary hysterectomies."

Focused exclusively on women's uterine health, Minerva Surgical is dedicated to investments in the technological innovation and evolution of its AUB device portfolio. The goal is to stop AUB, before a hysterectomy is the only option, by providing health practitioners with a suite of the most advanced, minimally invasive treatment solutions in every setting, from the operating room to the physician office.

ABOUT MINERVA SURGICAL

Minerva Surgical revolutionized the treatment of Abnormal Uterine Bleeding (AUB) with the introduction of its namesake product in 2015. At the time of launch, Minerva was the first innovation in endometrial ablation in 15 years and is still the best performing product in the history of clinical trials conducted for FDA approval. Today's Minerva system includes proprietary safety enhancements and software that measures changing uterine conditions in real time, an industry first. These features were designed exclusively for women's comfort and safety. The team at Minerva Surgical is wholly dedicated to the prioritization of women's uterine wellness and the advancement of technologies to treat AUB. For more information visit: endmyperiod.com.

1 American College of Obstetricians and Gynecologists. https://www.acog.org/patient-resources/faqs/gynecologic-problems/heavy-menstrual-bleeding. Accessed April 30, 2020.2 American Journal of Obstetrics and Gynecology. https://www.sciencedirect.com/science/article/abs/pii/S0002937814023552. Accessed April 30, 2020.

https://c212.net/c/img/favicon.png?sn=SF94374&sd=2020-05-12

View original content to download multimedia:http://www.prnewswire.com/news-releases/minerva-surgical-announces-acquisition-closing-of-boston-scientific-intrauterine-health-products-301057132.html

SOURCE Minerva Surgical

https://rt.prnewswire.com/rt.gif?NewsItemId=SF94374&Transmission_Id=202005121011PR_NEWS_USPR_____SF94374&DateId=20200512

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.